Chulavatnatol, SuvatnaChindavijak, BusbaChierakul, NitipatanaKlomsawat, Duangrat2009-05-272009-05-272003-08-02Chulavatnatol S, Chindavijak B, Chierakul N, Klomsawat D. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis. Journal of the Medical Association of Thailand. 2003 Aug; 86(8): 781-8http://imsear.searo.who.int/handle/123456789/39573Chotmaihet Thangphaet.The pharmacokinetics of ofloxacin were investigated in 11 drug-resistant pulmonary tuberculosis (TB) patients with a mean age (SD) of 38.09 (11.97) years. All patients received ofloxacin 10 mg/kg once daily combined with other active anti-TB drugs. Following an 8-h overnight fast, serum samples were drawn prior to and from 0.25 up to 24 hours after dosing. Serum ofloxacin concentrations were determined by high performance liquid chromatography (HPLC) assay. Pharmacokinetics of ofloxacin were well described by a linear, 2-compartment open model with first-order absorption and first-order elimination. Mean +/- SD of Cmax was 9.61 +/- 2.17 microg/ml occurred at 1.68 +/- 1.21 hours. Means +/- SD of AUC(0-24) and AUC(0-infinity) were 70.57 +/- 26.40 and 82.45 +/- 43.64 microg x h/ml, respectively. Ofloxacin distributed widely with a mean +/- SD of Vss/F of 1.37 +/- 0.24 L/kg. Mean +/- SD of CL/F was 8.19 +/- 2.53 L/h, whereas mean +/- SD of T(1/2beta) and mean residence time were 8.03 +/- 3.37 and 10.77 +/- 4.55 hours, respectively. The free Cmax/MIC of Mycobacterium tuberculosis of 7.7-15.4:1 was estimated. These suggested that ofloxacin 10 mg/kg once daily combined with other active anti-TB drugs provides sufficient Cmax/MIC ratio and long T(1/2beta) which supported its use in drug-resistant TB.engAdultAnti-Infective Agents --administration & dosageAntitubercular Agents --administration & dosageArea Under CurveChromatography, High Pressure LiquidDrug Therapy, CombinationHumansMiddle AgedOfloxacin --administration & dosagePyrazinamide --therapeutic useRifampin --therapeutic useTuberculosis, Multidrug-Resistant --drug therapyJournal Article